Mar 27 2010
Drug Safety Alliance (DSA), a global leader in drug safety and pharmacovigilance, announced that Dr. Elizabeth Garrard, PharmD, RPh, would participate in “Late Phase Drug Development World 2010,” a first of its kind strategic forum addressing challenges in drug development.
“We’re pleased in seeing increased pressure from regulatory agencies to focus on safety throughout the drug development process.”
The conference, held March 23-26 in Princeton, NJ, will feature interactive workshops, speaking presentations and panel discussions on topics ranging from risk management and cost effectiveness to best practices and operational planning. DSA’s Chief Safety Officer, Dr. Elizabeth Garrard, will participate in a discussion on “Regulatory challenges in post approval studies.”
“DSA is a long-time advocate for putting patient safety first, so our participation in this conference, where we can directly impact the conversation around late phase drug development, is crucial,” said Dr. Garrard. “We’re pleased in seeing increased pressure from regulatory agencies to focus on safety throughout the drug development process."
As a leader in patient safety and pharmacovigilance, DSA focuses on both adverse drug reactions (ADRs) in the post-market phase of the product life cycle and also on proactively identifying and incorporating newer approaches for managing safety in the clinical trial setting.